PDF(Pubmed)
Abstract：
UNASSIGNED: Ischemic heart disease (IHD) is a major global health issue and a leading cause of death. This study compares the effectiveness of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in the management of IHD, focusing on their impact on revascularization, myocardial infarction (MI), and post-procedural stroke. This study aimed to evaluate and compare the effectiveness of PCI and CABG in treating IHD based on an exhaustive literature review of the past 5 years, emphasizing recent advancements and outcomes in IHD management.
UNASSIGNED: A comprehensive literature review analyzed 32 randomized controlled trials (RCTs) retrieved from databases such as PubMed, Cochrane Library, and Google Scholar. The study specifically assessed the incidences of revascularization, stroke, and MI in patients treated with either PCI or CABG. The comparison between CABG and PCI exclusively focused on lesions with a SYNTAX score exceeding 32.
UNASSIGNED: Our findings highlight CABG\'s significant efficacy over PCI in reducing revascularization and MI. The aggregated Mantel-Haenszel (M-H) value for revascularization was 1.85 (95% confidence interval (CI): 1.65 - 2.07), signifying CABG\'s advantage. Additionally, CABG demonstrated superior performance in diminishing MI occurrences (M-H = 2.71, 95% CI: 1.13 - 6.53). In contrast, PCI was more effective in reducing stroke (M-H = 0.80, 95% CI: 0.60 - 1.10).
UNASSIGNED: The study confirms CABG\'s superiority in reducing revascularization and MI in IHD patients, highlighting PCI\'s effectiveness in reducing stroke risk. These findings underscore the importance of personalized treatment strategies in IHD management and emphasize the need for ongoing research and evidence-based guidelines to aid in treatment selection for IHD patients.
UNASSIGNED: A comprehensive literature review analyzed 32 randomized controlled trials (RCTs) retrieved from databases such as PubMed, Cochrane Library, and Google Scholar. The study specifically assessed the incidences of revascularization, stroke, and MI in patients treated with either PCI or CABG. The comparison between CABG and PCI exclusively focused on lesions with a SYNTAX score exceeding 32.
UNASSIGNED: Our findings highlight CABG\'s significant efficacy over PCI in reducing revascularization and MI. The aggregated Mantel-Haenszel (M-H) value for revascularization was 1.85 (95% confidence interval (CI): 1.65 - 2.07), signifying CABG\'s advantage. Additionally, CABG demonstrated superior performance in diminishing MI occurrences (M-H = 2.71, 95% CI: 1.13 - 6.53). In contrast, PCI was more effective in reducing stroke (M-H = 0.80, 95% CI: 0.60 - 1.10).
UNASSIGNED: The study confirms CABG\'s superiority in reducing revascularization and MI in IHD patients, highlighting PCI\'s effectiveness in reducing stroke risk. These findings underscore the importance of personalized treatment strategies in IHD management and emphasize the need for ongoing research and evidence-based guidelines to aid in treatment selection for IHD patients.
摘要：
■缺血性心脏病（IHD）是全球主要的健康问题，也是导致死亡的主要原因。这项研究比较了经皮冠状动脉介入治疗（PCI）和冠状动脉旁路移植术（CABG）在治疗IHD中的有效性。关注它们对血运重建的影响，心肌梗死（MI），和术后中风。这项研究旨在评估和比较PCI和CABG治疗IHD的有效性基于过去5年的详尽文献回顾。强调IHD管理的最新进展和成果。
■综合文献综述分析了从PubMed等数据库中检索到的32项随机对照试验（RCT），科克伦图书馆,谷歌学者。这项研究特别评估了血运重建的发生率，中风,接受PCI或CABG治疗的患者的MI。CABG和PCI之间的比较仅集中在SYNTAX评分超过32的病变上。
■我们的研究结果强调了CABG在减少血运重建和MI方面优于PCI的显著疗效。血运重建的Mantel-Haenszel(M-H)值是1.85(95%置信区间(CI):1.65-2.07),标志着CABG的优势。此外,CABG在减少MI发生率方面表现优异（M-H=2.71，95％CI：1.13-6.53）。相比之下,PCI在减少卒中方面更有效(M-H=0.80,95%CI:0.60-1.10)。
■该研究证实了CABG在减少IHD患者血运重建和MI方面的优越性，强调PCI在降低卒中风险方面的有效性。这些发现强调了个性化治疗策略在IHD管理中的重要性，并强调需要持续的研究和循证指南来帮助IHD患者的治疗选择。
■综合文献综述分析了从PubMed等数据库中检索到的32项随机对照试验（RCT），科克伦图书馆,谷歌学者。这项研究特别评估了血运重建的发生率，中风,接受PCI或CABG治疗的患者的MI。CABG和PCI之间的比较仅集中在SYNTAX评分超过32的病变上。
■我们的研究结果强调了CABG在减少血运重建和MI方面优于PCI的显著疗效。血运重建的Mantel-Haenszel(M-H)值是1.85(95%置信区间(CI):1.65-2.07),标志着CABG的优势。此外,CABG在减少MI发生率方面表现优异（M-H=2.71，95％CI：1.13-6.53）。相比之下,PCI在减少卒中方面更有效(M-H=0.80,95%CI:0.60-1.10)。
■该研究证实了CABG在减少IHD患者血运重建和MI方面的优越性，强调PCI在降低卒中风险方面的有效性。这些发现强调了个性化治疗策略在IHD管理中的重要性，并强调需要持续的研究和循证指南来帮助IHD患者的治疗选择。
